Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD in Cisplatin-Induced Nausea and Vomiting
NCT01046461Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 2010
- Primary completion
- Mar 2012
- Countries
- 1
- Sponsor
- Hallym University Medical Center
- Modality
- Small Molecules
- Drugs
- ramosetron
- Conditions
- chemotherapy-induced nausea and vomiting (CINV)
01
Overview
Phase 2, open-label trial of ramosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Hallym University Medical Center. Primary endpoint: Complete Response Rate (Overall Phase) at 5 days. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Chemotherapy-naïve patients aged 18-75 with solid tumors scheduled for cisplatin-based chemotherapy (>= 50 mg/m2).
04
Endpoints
Primary
Complete Response Rate (Overall Phase)
Beyond the preview
Go deeper on NCT01046461.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01046461.